FMP
Aurinia Pharmaceuticals Inc.
AUPH
NASDAQ
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
8.93 USD
0.05 (0.56%)
We are unable to load the chart at this time.
Mr. Peter S. Greenleaf M.B.A.
Healthcare
Biotechnology
NASDAQ
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
0001600620
CA05156V1022
05156V102
4464 Markham Street
12507084272
CA
300
Sep 3, 2014
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001600620
NASDAQ
Biotechnology
Healthcare
05156V102
CA05156V1022
CA
8.93
1.46
1.2M
1.28B
-
4.71-9.74
6.6
-
-
-
-
-59.53
-
https://www.auriniapharma.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.